Carlsmed, Inc.CARL

Carlsmed, Inc. cleared its aprevo interbody implants for cervical spine fusion in November 2024, then launched the aprevo Technology Platform for US cervical fusion surgeries in December 2025, positioning itself as a ‘personalized procedural solutions’ provider that uses patient data to design custom devices and surgical plans. The company’s product pages promise devices ‘designed to optimize surgical workflows’ and ‘improve clinical outcomes,’ a pitch that reads like a Silicon Valley pitch deck filtered through an orthopaedic theatre. (source: aprevo® Technology Platform - Carlsmed, https://carlsmed.com/aprevo-technology-platform/; Personalized Procedural Solutions - Carlsmed, https://carlsmed.com/personalized-procedural-solutions/)

By the end of March 2026, however, the balance sheet had not warmed to the polished story. The company reported net income attributable to parent of minus $8.7 million, operating loss of minus $9.3 million, and negative operating cash flow of minus $13.0 million for the quarter, while assets totalled $118.8 million and stockholders’ equity $92.2 million. Cash and cash equivalents stood at $73.0 million and short-term investments at $24.0 million, giving the firm a comfortable cash cushion even as the top line remains unpublished. (source: CARL 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1794546/000179454626000011/carl-20260331.htm)

Carlsmed’s diluted loss per share was $0.32 for the quarter on 26.8 million diluted shares, and the company’s inventory rose by $771,000 to $2.1 million. Capital expenditure was a trifling $79,000, while research and development expense ran to $5.2 million, a ratio that would make any factory owner blush. The firm stresses that no single customer contributed more than 10% of revenue in the quarter, yet it has not disclosed any revenue figure at all, leaving analysts to guess whether the aprevo Technology Platform is generating fees, royalties, or simply the sound of surgeons downloading PDFs. (source: CARL 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1794546/000179454626000011/carl-20260331.htm)

The company’s 8-K filed on 3 June 2026 is a reminder that the board has been busy with ownership filings rather than revenue filings: the document catalogues multiple Form 4 submissions on 22 June 2026, a procession of insider trades and grants that reads like a masterclass in disclosure theatre. Meanwhile, the FASB’s ASU 2025-07 on derivatives and revenue recognition is parked in the footnotes, hinting that any future customer payments may involve share-based or derivative consideration-useful for optics, less useful for clarity. (source: CARL 8-K, 2026-06-03, https://www.sec.gov/Archives/edgar/data/1794546/000119312526255404/carl-20260603.htm)

For readers seeking a valuation anchor, the filing index shows no revenue line in the latest quarterly report, so any price-to-sales or revenue-based metric would be pure speculation. The company’s market presence is real-FDA clearance, a launched platform, and a tidy cash pile-but the missing revenue figure is the elephant in the spine clinic. Until Carlsmed publishes topline numbers, the market is left to trade on hope, disclosure documents, and the occasional Form 4. (source: CARL SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1794546)

What changed this week: nothing that changes the revenue mystery. The 10-Q remains the latest public financial statement, and the SEC’s companyfacts JSON confirms that revenue, gross profit, and operating segments are not yet disclosed in XBRL for the relevant period. The company’s cash burn, inventory build, and R&D intensity are all documented, but the headline the market actually wants is still missing. (source: CARL SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001794546.json)

What would deepen the file: a quarterly update that discloses revenue, customer mix, average selling price, or utilisation rates for the aprevo Technology Platform. Absent that, the company’s story remains a pitch deck in search of a P&L. (source: CARL SEC submissions JSON, https://data.sec.gov/submissions/CIK0001794546.json)